Core Viewpoint - The company, Qianxin Biologics-B (02509), has received clinical trial implicit approval from the National Medical Products Administration for its self-developed long-acting bispecific antibody QX027N, aimed at treating asthma and atopic dermatitis, marking a significant step in its innovative dual antibody matrix in the field of autoimmune and allergic diseases [1] Group 1 - The candidate drug QX027N represents an important achievement in the company's bispecific antibody research and signifies further progress in its collaborative layout in respiratory and dermatological disease areas [1] - The clinical approval addresses the urgent clinical needs of millions of asthma and atopic dermatitis patients worldwide, indicating the company's commitment to advancing innovative therapies [1] - The company aims to provide more efficient, safer, and more convenient treatment options for patients through continuous development and clinical translation of innovative therapies [1]
荃信生物-B(02509)：长效双抗QX027N获得两项临床试验默示许可